Safety of Disclosing Amyloid Imaging Results to MCI and AD Patients

[1]  J. Ioannidis.  The Proposal to Lower P Value Thresholds to .005. , 2018, JAMA.

[2]  M. Jinzaki,et al.  The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline , 2017, International Psychogeriatrics.

[3]  E. Vidoni,et al.  Safety of disclosing amyloid status in cognitively normal older adults , 2017, Alzheimer's & Dementia.

[4]  Keith A. Johnson,et al.  Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. , 2017, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[5]  Klaus P. Ebmeier,et al.  Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study , 2017, JAMA psychiatry.

[6]  C. Jack,et al.  The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology , 2017, Neurobiology of Aging.

[7]  C. Jack,et al.  Alzheimer's disease: The next frontier—Special Report 2017 , 2017, Alzheimer's & Dementia.

[8]  M. Carrillo,et al.  The biomarker-based diagnosis of Alzheimer's disease. 1—ethical and societal issues , 2017, Neurobiology of Aging.

[9]  Keith A. Johnson,et al.  Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. , 2016, JAMA psychiatry.

[10]  A. Fagan,et al.  Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. , 2016, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[11]  C. Jack,et al.  THE BIOMARKER-BASED DIAGNOSIS OF ALZHEIMER’S DISEASE: LESSONS FROM ONCOLOGY , 2016, Alzheimer's & Dementia.

[12]  Kristine Yaffe,et al.  Trajectories of Depressive Symptoms in Older Adults and Risk of Dementia. , 2016, JAMA psychiatry.

[13]  Craig Ritchie,et al.  Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit , 2016, Alzheimer's & Dementia.

[14]  P. Snyder,et al.  Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability , 2016, Alzheimer's & Dementia.

[15]  M. Carrillo,et al.  Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary , 2016, Alzheimer's & Dementia.

[16]  Norman L. Foster,et al.  Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations , 2015, Alzheimer's & dementia.

[17]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[18]  C. Rowe,et al.  Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. , 2015, JAMA psychiatry.

[19]  H. Blumberg,et al.  Neurobiological risk factors for suicide: insights from brain imaging. , 2014, American journal of preventive medicine.

[20]  Pedro Rosa-Neto,et al.  Use of amyloid PET across the spectrum of Alzheimer’s disease: clinical utility and associated ethical issues , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[21]  Keith A. Johnson,et al.  Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants , 2014, Alzheimer's Research & Therapy.

[22]  C. Rowe,et al.  Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study , 2014, British Journal of Psychiatry.

[23]  R. Adelman,et al.  Caregiver burden: a clinical review. , 2014, JAMA.

[24]  C. Rowe,et al.  Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.

[25]  J. Roberts,et al.  Genetic susceptibility testing for neurodegenerative diseases: Ethical and practice issues , 2013, Progress in Neurobiology.

[26]  W. Klunk,et al.  Disclosure of amyloid imaging results to research participants: Has the time come? , 2013, Alzheimer's & Dementia.

[27]  J. Roberts,et al.  Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. , 2013, Neurodegenerative disease management.

[28]  J. Karlawish,et al.  Risk disclosure and preclinical Alzheimer’s disease clinical trial enrollment , 2013, Alzheimer's & Dementia.

[29]  R. Snaith,et al.  The hospital anxiety and depression scale. , 2013, Acta psychiatrica Scandinavica.

[30]  J. Burns,et al.  Should we disclose amyloid imaging results to cognitively normal individuals? , 2013, Neurodegenerative disease management.

[31]  J. Kaye,et al.  Dementia specialists and early adoption of amyloid imaging. , 2012, Journal of Alzheimer's disease : JAD.

[32]  S. Gauthier,et al.  Ethical issues in Alzheimer’s disease: an overview , 2012, Expert review of neurotherapeutics.

[33]  G. Small,et al.  Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. , 2012, Archives of neurology.

[34]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[35]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[36]  G. Frisoni,et al.  Diagnosis Disclosure of Prodromal Alzheimer Disease-Ethical Analysis of Two Cases , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[37]  G. Linazasoro,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.

[38]  C. Rowe,et al.  Imaging β-amyloid burden in aging and dementia , 2007, Neurology.

[39]  Kathy J. Horvath,et al.  Genetic susceptibility for Alzheimer's disease: Why did adult offspring seek testing? , 2005, American journal of Alzheimer's disease and other dementias.

[40]  R. Green,et al.  Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial , 2004, Genetics in Medicine.

[41]  Deb Feldman-Stewart,et al.  Validation of a Decision Regret Scale , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[42]  T. Marteau,et al.  The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). , 1992, The British journal of clinical psychology.

[43]  J. Yesavage,et al.  Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .

[44]  J. Karlawish,et al.  Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults , 2018, JAMA neurology.

[45]  S. Pal,et al.  Neuroimaging A systematic review and meta-analysis of 18 F-labeled amyloid imaging in Alzheimer's disease , 2015 .

[46]  C. Rowe,et al.  Brain amyloid imaging. , 2013, Journal of nuclear medicine technology.

[47]  Paco Martorell,et al.  Monetary costs of dementia in the United States. , 2013, The New England journal of medicine.

[48]  J. Stockman.  Disclosure of APOE Genotype for Risk of Alzheimer's Disease , 2011 .

[49]  S. Okazaki,et al.  CES-D scale , 2006 .

[50]  M. Leok.  The use of , 1996 .